/IMMX
IMMX Stock - Immix Biopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$5.72+0.18%
+$0.01 (+0.18%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+109.8%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMMX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.66 – $5.78
TARGET (TP)$12.00
STOP LOSS$5.26
RISK/REWARD1:13.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.33
52W High$7.73
52W Low$1.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-22,674,680 | $-16,141,113 | $-8,218,948 | $-1,352,014 | $-453,852 |
| Net Income | $-21,613,376 | $-15,426,048 | $-8,229,713 | $-24,383,879 | $-1,147,863 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.76 | $-0.89 | $-0.59 | $-6.64 | $-0.15 |
Company Overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IMMXBeat Rate
33%
Last 12 quarters
Avg Surprise
-6.2%
EPS vs Estimate
Beats / Misses
4/7
1 met exactly
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
-4.3%
$-0.24vs$-0.23
Q2 24
+4.3%
$-0.22vs$-0.23
Q3 24
+28.6%
$-0.15vs$-0.21
Q4 24
-50.0%
$-0.24vs$-0.16
Q1 25
+36.0%
$-0.16vs$-0.25
Q2 25
+34.8%
$-0.15vs$-0.23
Q3 25
-4.8%
$-0.22vs$-0.21
Q4 25
-26.3%
$-0.24vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.23 | $-0.15 | +34.8% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.16 | $-0.24 | -50.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.21 | $-0.15 | +28.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.23 | $-0.23 | 0.0% | = MET |
Q3 2023 | Aug 11, 2023 | $-0.17 | $-0.24 | -41.2% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.14 | $-0.18 | -28.6% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | — | $-0.11 | — | — |
Q3 2022 | Aug 12, 2022 | — | $-0.11 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.10 | — | — |
Q1 2022 | Mar 28, 2022 | — | $-3.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.06 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.12 | — | — |
Latest News
Immix Biopharma shares are trading higher after HC Wainwright & Co. raised the price target from $8 to $12.
📈 PositiveBenzinga•Dec 9, 2025, 05:14 PM
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $12
📈 PositiveBenzinga•Dec 9, 2025, 03:32 PM
IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company reported that NXC-201 demonstrated a 75% complete response rate, with MRD negativity in additional patients potentially raising the future CR rate to 95%, and plans for NEXICART-2 final readout and BLA submission in 2026.
➖ NeutralBenzinga•Dec 8, 2025, 03:21 PM
Immix Biopharma shares are trading higher after the company reported that NXC-201 demonstrated a 75% complete response rate, with MRD negativity in additional patients potentially raising the future CR rate to 95%, and plans for NEXICART-2 final readout and BLA submission in 2026.
📈 PositiveBenzinga•Dec 8, 2025, 01:50 PM
Reported Sunday, Immix Biopharma Says NXC-201 Shows 75% CR By Independent Review, With MRD Negativity Potentially Raising CR To 95%
📈 PositiveBenzinga•Dec 8, 2025, 08:10 AM
Immix Biopharma Priced Underwritten Registered Offering Of 19,117,646 Shares Of Common Stock At $5.10/Share
➖ NeutralBenzinga•Dec 7, 2025, 11:27 PM
Immix Biopharma To Present Phase 1/2 Interim Results From US NXC-201 NEXICART-2 Trial In Relapsed/Refractory AL Amyloidosis At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 01:48 PM
Immix Biopharma To Present An Abstract On Its Therapy NXC-201 At The ASH 67th Annual Meeting December 6–9, 2025, In Orlando, Florida
📈 PositiveBenzinga•Oct 7, 2025, 08:10 PM
Immix Biopharma Surpasses 50% Enrollment In NEXICART-2 Trial For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis, Advancing Toward BLA Submission
📈 PositiveBenzinga•Sep 18, 2025, 05:32 PM
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $8
📈 PositiveBenzinga•Sep 12, 2025, 10:35 AM
Immix Biopharma Gains Strategic Investment From Goose Capital And Dr. Nancy T. Chang; Financial Terms Not Disclosed
📈 PositiveBenzinga•Sep 8, 2025, 08:08 PM
Frequently Asked Questions about IMMX
What is IMMX's current stock price?
Immix Biopharma, Inc. (IMMX) is currently trading at $5.72 per share. The stock has moved +0.18% today.
What is the analyst price target for IMMX?
The average analyst price target for IMMX is $12.00, based on 1 analyst.
What sector is Immix Biopharma, Inc. in?
Immix Biopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMMX's market cap?
Immix Biopharma, Inc. has a market capitalization of $0.19 billion, making it a small-cap company.
Does IMMX pay dividends?
No, Immix Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
ORMP
Oramed Pharmaceuticals Inc.
$2.93
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TIL
Instil Bio, Inc.
$11.27
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to IMMX for comparison